INCY News and Press, Incyte Corporation From 10/05/20

The first participant has been dosed in a China-based Phase 3 clinical trial, PODIUM-304, evaluating Zai Lab Limited (ZLAB) and Incyte's (INCY) PD-1 inhibitor retifanlimab, combined with platinum-based chemo, in treatment-naïve patients with metastatic non-small cell lung cancer ((NSCLC)...

The following slide deck was published by Incyte Corporation in conjunction with this event. For further details see: Incyte (INCY) Presents at ESMO Virtual Congress - Slideshow

In a note RBC regards yesterday's selloff in biotechs as an "especially attractive entry point" for leading names such names as Gilead Sciences ([[GILD]] -2.1%), Sarepta Therapeutics ([[SRPT]] -1.8%) and Constellation Pharmaceuticals ([[CNST]] -5.0%).Analysts, led by Brian Abrahams, believe G...

Incyte ( INCY ) is an innovative pharmaceutical company that had its stock price peak at $140.11 in 2017 when it was considered to be a likely acquisition target. Most recently a drug it developed and licensed to Eli Lilly ( LLY ), Olumiant or baricitinib, showed promise as a treatment for CO...

INDIANAPOLIS , Sept. 18, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for baricitinib for the treatment of ...

A 94-subject Phase 2 clinical trial, PODIUM-202 , evaluating Incyte's (NASDAQ: INCY ) PD-1 inhibitor retifanlimab (formerly INCMGA0012) in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed after platinum-based chemo showed a tr...

Independent central review confirmed responses include 1 complete response, 12 partial responses and 33 stable disease for an objective response rate of 14% and disease control rate of 49% Responses were observed regardless of PD-L1 status, presence of liver metastases or HIV+ stat...

- Analyst and investor conference call and webcast scheduled for Tuesday, September 29, 2020 at 9:00 a.m. EDT / 3:00 p.m. CEST Incyte (Nasdaq:INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced that the companies intend to host a con...

Mergers have been lagging Mergers for 2020 have vastly lagged last year. This has been a cause of concern for me in judging the health of the stock market. For the raison d'etres of Wall Street is not to make us rich, it's to create a source of equity capital to build companies. Our role...

Eli Lilly (NYSE: LLY ) announces positive preliminary results from an NIAID-sponsored clinical trial, ACTT-2 , evaluating the combination of baricitinib and Gilead Sciences' (NASDAQ: GILD ) remdesivir in more than 1,000 hospitalized COVID-19 patients. More news on: Eli Lilly and Com...